Amneal Pharmaceuticals, Inc.
AMRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2,447 | $1,062 | $300 | $713 |
| - Cash | $111 | $92 | $26 | $248 |
| + Debt | $2,593 | $2,751 | $2,845 | $2,876 |
| Enterprise Value | $4,930 | $3,721 | $3,120 | $3,342 |
| Revenue | $2,794 | $2,394 | $2,212 | $2,094 |
| % Growth | 16.7% | 8.2% | 5.7% | – |
| Gross Profit | $1,020 | $864 | $791 | $769 |
| % Margin | 36.5% | 36.1% | 35.8% | 36.7% |
| EBITDA | $440 | $501 | $440 | $401 |
| % Margin | 15.7% | 20.9% | 19.9% | 19.2% |
| Net Income | -$117 | -$84 | -$130 | $11 |
| % Margin | -4.2% | -3.5% | -5.9% | 0.5% |
| EPS Diluted | -0.38 | -0.48 | -0.86 | 0.07 |
| % Growth | 20.8% | 44.2% | -1,328.6% | – |
| Operating Cash Flow | $295 | $346 | $65 | $242 |
| Capital Expenditures | -$75 | -$69 | -$91 | -$48 |
| Free Cash Flow | $220 | $276 | -$25 | $194 |